nach oben

Calcified Tissue International

Erschienen in:

23.04.2020 | Review

Congenital Conditions of Hypophosphatemia in Children

verfasst von: Erik Allen Imel

Erschienen in: Calcified Tissue International | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Great strides over the past few decades have increased our understanding of the pathophysiology of hypophosphatemic disorders. Phosphate is critically important to a variety of physiologic processes, including skeletal growth, development and mineralization, as well as DNA, RNA, phospholipids, and signaling pathways. Consequently, hypophosphatemic disorders have effects on multiple systems, and may cause a variety of nonspecific signs and symptoms. The acute effects of hypophosphatemia include neuromuscular symptoms and compromise. However, the dominant effects of chronic hypophosphatemia are the effects on musculoskeletal function including rickets, osteomalacia and impaired growth during childhood. While the most common causes of chronic hypophosphatemia in children are congenital, some acquired conditions also result in hypophosphatemia during childhood through a variety of mechanisms. Improved understanding of the pathophysiology of these congenital conditions has led to novel therapeutic approaches. This article will review the pathophysiologic causes of congenital hypophosphatemia, their clinical consequences and medical therapy.

Imel EA, Econs MJ (2012) Approach to the hypophosphatemic patient. J Clin Endocrinol Metab 97:696–706PubMedPubMedCentralCrossRef

Imel EA, Carpenter TO (2018) Rickets: the skeletal disorders of impaired calcium or phosphate availability. In: Radovick S, Misra M (eds) Pediatric endocrinology: a practical clinical guide. Springer, New York, pp 497–524CrossRef

Demay MB, Sabbagh Y, Carpenter TO (2007) Calcium and vitamin D: what is known about the effects on growing bone. Pediatrics 119(Suppl 2):S141–144PubMedCrossRef

Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef

Thacher TD, Fischer PR, Pettifor JM, Lawson JO, Manaster BJ, Reading JC (2000) Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr 46:132–139PubMedCrossRef

DiMeglio LA, Imel EA (2019) Calcium and phosphate: hormonal regulation and metabolism. In: Burr DB, Allen MR (eds) Basic and applied bone biology. Elsevier Academic Press, New York, pp 257–282CrossRef

Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310PubMedCrossRef

Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G (1986) Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron 44:125–128PubMedCrossRef

El-Maouche D, Dumitrescu CE, Andreopoulou P, Gafni RI, Brillante BA, Bhattacharyya N, Fedarko NS, Collins MT (2016) Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos Int 27:2345–2353PubMedCrossRef

10.

Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef

11.

Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49:546–553PubMedCrossRef

12.

Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97:3357–3365PubMedCrossRef

13.

Gkentzi D, Efthymiadou A, Kritikou D, Chrysis D (2014) Fibroblast growth factor 23 and Klotho serum levels in healthy children. Bone 66:8–14PubMedCrossRef

14.

Ali FN, Josefson J, Mendez AJ, Mestan K, Wolf M (2016) Cord blood ferritin and fibroblast growth factor-23 levels in neonates. J Clin Endocrinol Metab 101:1673–1679PubMedPubMedCentralCrossRef

15.

Holmlund-Suila E, Viljakainen H, Ljunggren O, Hytinantti T, Andersson S, Makitie O (2016) Fibroblast growth factor 23 concentrations reflect sex differences in mineral metabolism and growth in early infancy. Horm Res Paediatr 85:232–241PubMedCrossRef

16.

Holmlund-Suila E, Enlund-Cerullo M, Valkama S, Hauta-Alus H, Rosendahl J, Helve O, Hytinantti T, Viljakainen H, Andersson S, Makitie O (2017) Sex and iron modify fibroblast growth factor 23 (FGF23) concentration in 1-year-old children. J Clin Endocrinol Metab 102:4526–4533PubMedCrossRef

17.

Imel EA, Hui SL, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedCrossRef

18.

Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef

19.

Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ (2011) Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 96:3541–3549PubMedPubMedCentralCrossRef

20.

Folsom LJ, Imel EA (2015) Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action. Curr Osteoporos Rep 13:78–87PubMedCrossRef

21.

Bergwitz C, Miyamoto KI (2019) Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy. Pflugers Arch 471:149–163PubMedCrossRef

22.

Hohenfellner K, Rauch F, Ariceta G, Awan A, Bacchetta J, Bergmann C, Bechtold S, Cassidy N, Deschenes G, Elenberg E, Gahl WA, Greil O, Harms E, Herzig N, Hoppe B, Koeppl C, Lewis MA, Levtchenko E, Nesterova G, Santos F, Schlingmann KP, Servais A, Soliman NA, Steidle G, Sweeney C, Treikauskas U, Topaloglu R, Tsygin A, Veys K, Vigier R, Zustin J, Haffner D (2019) Management of bone disease in cystinosis: statement from an international conference. J Inherit Metab Dis 42:1019–1029PubMedPubMedCentralCrossRef

23.

Zivicnjak M, Schnabel D, Billing H, Staude H, Filler G, Querfeld U, Schumacher M, Pyper A, Schroder C, Bramswig J, Haffner D, Hypophosphatemic Rickets Study Group of Arbeitsgemeinschaft fur Padiatrische E, Gesellschaft fur Padiatrische N (2011) Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets. Pediatr Nephrol 26:223–231PubMedCrossRef

24.

Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL (2011) A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26:1381–1388PubMedCrossRef

25.

Gonzalez Ballesteros LF, Ma NS, Gordon RJ, Ward L, Backeljauw P, Wasserman H, Weber DR, DiMeglio LA, Gagne J, Stein R, Cody D, Simmons K, Zimakas P, Topor LS, Agrawal S, Calabria A, Tebben P, Faircloth R, Imel EA, Casey L, Carpenter TO (2017) Unexpected widespread hypophosphatemia and bone disease associated with elemental formula use in infants and children. Bone 97:287–292PubMedPubMedCentralCrossRef

26.

Creo AL, Epp LM, Buchholtz JA, Tebben PJ (2018) Prevalence of metabolic bone disease in tube-fed children receiving elemental formula. Horm Res Paediatr 90:291–298PubMedCrossRef

27.

Upgraded Neocate Junior (2019). Neocate Syneo. https://www.neocate.com/junior/. Accessec 15 Nov 2015

28.

Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL (1994) Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378–1383PubMed

29.

Beck-Nielsen SS, Brock-Jacobsen B, Gram J, Brixen K, Jensen TK (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160:491–497PubMedCrossRef

30.

Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol

31.

Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK (2008) Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118:722–734PubMedPubMedCentral

32.

Onishi T, Umemura S, Shintani S, Ooshima T (2008) Phex mutation causes overexpression of FGF23 in teeth. Arch Oral Biol 53:99–104PubMedCrossRef

33.

Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235–1239PubMedCrossRef

34.

Boukpessi T, Hoac B, Coyac BR, Leger T, Garcia C, Wicart P, Whyte MP, Glorieux FH, Linglart A, Chaussain C, McKee MD (2017) Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone 95:151–161PubMedCrossRef

35.

Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591–3597PubMedCrossRef

36.

Gizard A, Rothenbuhler A, Pejin Z, Finidori G, Glorion C, de Billy B, Linglart A, Wicart P (2017) Outcomes of orthopedic surgery in a cohort of 49 patients with X-linked hypophosphatemic rickets (XLHR). Endocr Connect 6:566–573PubMedPubMedCentralCrossRef

37.

Biosse Duplan M, Coyac BR, Bardet C, Zadikian C, Rothenbuhler A, Kamenicky P, Briot K, Linglart A, Chaussain C (2017) Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia. J Dent Res 96:388–395PubMedCrossRef

38.

Connor J, Olear EA, Insogna KL, Katz L, Baker S, Kaur R, Simpson CA, Sterpka J, Dubrow R, Zhang JH, Carpenter TO (2015) Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab 100:3625–3632PubMedPubMedCentralCrossRef

39.

Econs MJ, Samsa GP, Monger M, Drezner MK, Feussner JR (1994) X-linked hypophosphatemic rickets—a disease often unknown to affected patients. Bone and mineral 24:17–24PubMedCrossRef

40.

Beck-Nielsen SS, Brusgaard K, Rasmussen LM, Brixen K, Brock-Jacobsen B, Poulsen MR, Vestergaard P, Ralston SH, Albagha OM, Poulsen S, Haubek D, Gjorup H, Hintze H, Andersen MG, Heickendorff L, Hjelmborg J, Gram J (2010) Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 87:108–119PubMedCrossRef

41.

Insogna KL, Briot K, Imel EA, Kamenicky P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, A Investigators (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33:1383–1393PubMedCrossRef

42.

Reid IR, Hardy DC, Murphy WA, Teitelbaum SL, Bergfeld MA, Whyte MP (1989) X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults. Medicine 68:336–352PubMedCrossRef

43.

Polisson RP, Martinez S, Khoury M, Harrell RM, Lyles KW, Friedman N, Harrelson JM, Reisner E, Drezner MK (1985) Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313:1–6PubMedCrossRef

44.

Liang G, Katz LD, Insogna KL, Carpenter TO, Macica CM (2009) Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int 85:235–246PubMedPubMedCentralCrossRef

45.

Mills ES, Iorio L, Feinn RS, Duignan KM, Macica CM (2019) Joint replacement in X-linked hypophosphatemia. J Orthop 16:55–60PubMedCrossRef

46.

Rothenbuhler A, Fadel N, Debza Y, Bacchetta J, Diallo MT, Adamsbaum C, Linglart A, Di Rocco F (2019) High incidence of cranial synostosis and Chiari I malformation in children with X-linked hypophosphatemic rickets (XLHR). J Bone Miner Res 34:490–496PubMedCrossRef

47.

Gjorup H, Beck-Nielsen SS, Haubek D (2017) Craniofacial and dental characteristics of patients with vitamin-D-dependent rickets type 1A compared to controls and patients with X-linked hypophosphatemia. Clin Oral Investig

48.

Gjorup H, Sonnesen L, Beck-Nielsen SS, Haubek D (2014) Upper spine morphology in hypophosphatemic rickets and healthy controls: a radiographic study. Eur J Orthod 36:217–225PubMedCrossRef

49.

Davies M, Kane R, Valentine J (1984) Impaired hearing in X-linked hypophosphataemic (vitamin-D-resistant) osteomalacia. Ann Intern Med 100:230–232PubMedCrossRef

50.

Fishman G, Miller-Hansen D, Jacobsen C, Singhal VK, Alon US (2004) Hearing impairment in familial X-linked hypophosphatemic rickets. Eur J Pediatr 163:622–623PubMed

51.

Chesher D, Oddy M, Darbar U, Sayal P, Casey A, Ryan A, Sechi A, Simister C, Waters A, Wedatilake Y, Lachmann RH, Murphy E (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41(5):865–876PubMedPubMedCentralCrossRef

52.

White KE, Evans WE, O'Riordan JL, Speer MC, Econs MJ, Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM, The_ADHR_Consortium (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef

53.

White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedCrossRef

54.

Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 108:E1146–1155PubMedCrossRefPubMedCentral

55.

Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681PubMedCrossRef

56.

Durham BH, Joseph F, Bailey LM, Fraser WD (2007) The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 44:463–466PubMedCrossRef

57.

Braithwaite V, Prentice AM, Doherty C, Prentice A (2012) FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012:27PubMedPubMedCentralCrossRef

58.

Braithwaite V, Jones KS, Assar S, Schoenmakers I, Prentice A (2014) Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children. Endocr Connect 3:1–10PubMedCrossRef

59.

Imel EA, Liu Z, McQueen AK, Acton D, Acton A, Padgett LR, Peacock M, Econs MJ (2016) Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women. Bone 86:98–105PubMedPubMedCentralCrossRef

60.

Imel EA, Liu Z, Coffman M, Acton D, Mehta R, Econs MJ (2020) Oral Iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets. J Bone Miner Res 35:231–238PubMedCrossRef

61.

Kapelari K, Kohle J, Kotzot D, Hogler W (2015) Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 100:3388–3392PubMedCrossRef

62.

Imel EA, Gray AK, Padgett LR, Econs MJ (2014) Iron and fibroblast growth factor 23 in X-linked hypophosphatemia. Bone 60:87–92PubMedCrossRef

63.

Hum JM, Clinkenbeard EL, Ip C, Cass TA, Allen M, White KE (2017) The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1alpha expression. Bone Rep 6:38–43PubMedPubMedCentralCrossRef

64.

Schouten BJ, Doogue MP, Soule SG, Hunt PJ (2009) Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 46:167–169PubMedCrossRef

65.

Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG (2009) FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94:2332–2337PubMedCrossRef

66.

Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T (2009) Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45:814–816PubMedCrossRef

67.

Bishay RH, Ganda K, Seibel MJ (2017) Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab 8:14–19PubMedCrossRef

68.

Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W (2018) Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3:23

69.

Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793–1803PubMedCrossRef

70.

Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310–1315PubMedPubMedCentralCrossRef

71.

Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM (2006) DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248–1250PubMedPubMedCentralCrossRef

72.

Mäkitie O, Pereira RC, Kaitila I, Turan S, Bastepe M, Laine T, Kröger H, Cole WG, Jüppner H (2010) Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Miner Res 25:2165–2174PubMedPubMedCentralCrossRef

73.

Turan S, Aydin C, Bereket A, Akcay T, Güran T, Yaralioglu BA, Bastepe M, Jüppner H (2010) Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone 46:402–409PubMedCrossRef

74.

Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD (2008) Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295:E254–261PubMedPubMedCentralCrossRef

75.

Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Hohne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nurnberg P (2003) Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34:379–381PubMedCrossRef

76.

Ruf N, Uhlenberg B, Terkeltaub R, Nürnberg P, Rutsch F (2005) The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 25:98–98PubMedCrossRef

77.

Rutsch F, Boyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nurnberg P, Terkeltaub R (2008) Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 1:133–140PubMedPubMedCentralCrossRef

78.

Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273–278PubMedPubMedCentralCrossRef

79.

Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86:267–272PubMedPubMedCentralCrossRef

80.

Nitschke Y, Rutsch F (2017) Inherited arterial calcification syndromes: etiologies and treatment concepts. Curr Osteoporos Rep 15:255–270PubMedCrossRef

81.

Mackenzie NC, Zhu D, Milne EM, van’t Hof R, Martin A, Darryl Quarles L, Millan JL, Farquharson C, MacRae VE (2012) Altered bone development and an increase in FGF-23 expression in Enpp1(-/-) mice. PLoS ONE 7:e32177PubMedPubMedCentralCrossRef

82.

Ferreira CR, Ziegler SG, Gupta A, Groden C, Hsu KS, Gahl WA (2016) Treatment of hypophosphatemic rickets in generalized arterial calcification of infancy (GACI) without worsening of vascular calcification. Am J Med Genet 170A:1308–1311PubMedCrossRef

83.

Thumbigere-Math V, Alqadi A, Chalmers NI, Chavez MB, Chu EY, Collins MT, Ferreira CR, FitzGerald K, Gafni RI, Gahl WA, Hsu KS, Ramnitz MS, Somerman MJ, Ziegler SG, Foster BL (2018) Hypercementosis associated with ENPP1 mutations and GACI. J Dent Res 97:432–441PubMedCrossRef

84.

Saito T, Shimizu Y, Hori M, Taguchi M, Igarashi T, Fukumoto S, Fujitab T (2011) A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone 49:913–916PubMedCrossRef

85.

Mehta P, Mitchell A, Tysoe C, Caswell R, Owens M, Vincent T (2012) Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification. Rheumatology 51:1919–1921PubMedCrossRef

86.

Rafaelsen SH, Raeder H, Fagerheim AK, Knappskog P, Carpenter TO, Johansson S, Bjerknes R (2013) Exome sequencing reveals FAM20c mutations associated with fibroblast growth factor 23-related hypophosphatemia, dental anomalies, and ectopic calcification. J Bone Miner Res 28:1378–1385PubMedCrossRef

87.

Wang X, Wang S, Li C, Gao T, Liu Y, Rangiani A, Sun Y, Hao J, George A, Lu Y, Groppe J, Yuan B, Feng JQ, Qin C (2012) Inactivation of a novel FGF23 regulator, FAM20C, leads to hypophosphatemic rickets in mice. PLoS Genet 8:e1002708PubMedPubMedCentralCrossRef

88.

Tagliabracci VS, Engel JL, Wiley SE, Xiao J, Gonzalez DJ, Nidumanda Appaiah H, Koller A, Nizet V, White KE, Dixon JE (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 111:5520–5525PubMedCrossRefPubMedCentral

89.

Hartley I, Zhadina M, Collins MT, Boyce AM (2019) Fibrous dysplasia of bone and McCune–Albright syndrome: a bench to bedside review. Calcif Tissue Int 104:517–529PubMedPubMedCentralCrossRef

90.

Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune–Albright syndrome. N Engl J Med 325:1688–1695PubMedCrossRef

91.

Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683–692PubMedPubMedCentralCrossRef

92.

Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Robey PG (2001) Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806–813PubMedCrossRef

93.

Bhattacharyya N, Wiench M, Dumitrescu C, Connolly BM, Bugge TH, Patel HV, Gafni RI, Cherman N, Cho M, Hager GL, Collins MT (2012) Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 27:1132–1141PubMedCrossRef

94.

Menascu S, Donner EJ (2008) Linear nevus sebaceous syndrome: case reports and review of the literature. Pediatr Neurol 38:207–210PubMedCrossRef

95.

Lim YH, Ovejero D, Sugarman JS, Deklotz CM, Maruri A, Eichenfield LF, Kelley PK, Juppner H, Gottschalk M, Tifft CJ, Gafni RI, Boyce AM, Cowen EW, Bhattacharyya N, Guthrie LC, Gahl WA, Golas G, Loring EC, Overton JD, Mane SM, Lifton RP, Levy ML, Collins MT, Choate KA (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23:397–407PubMedCrossRef

96.

Hoffman WH, Jueppner HW, Deyoung BR, O'Dorisio MS, Given KS (2005) Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet 134:233–236PubMedCrossRef

97.

Ovejero D, Lim YH, Boyce AM, Gafni RI, McCarthy E, Nguyen TA, Eichenfield LF, DeKlotz CM, Guthrie LC, Tosi LL, Thornton PS, Choate KA, Collins MT (2016) Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos Int 27:3615–3626PubMedPubMedCentralCrossRef

98.

Kuthiroly S, Yesodharan D, Ghosh A, White KE, Nampoothiri S (2017) Osteoglophonic dysplasia: phenotypic and radiological clues. J Pediatr Genet 6:247–251PubMedPubMedCentralCrossRef

99.

White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361–367PubMedCrossRef

100.

Han X, Xiao Z, Quarles LD (2015) Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 290:10447–10459PubMedPubMedCentralCrossRef

101.

Wu A-L, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, Wyatt SK, Gandham VD, Carano RAD, Sonoda J (2013) Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS ONE 8:e57322–e57322PubMedPubMedCentralCrossRef

102.

Xiao Z, Huang J, Cao L, Liang Y, Han X, Quarles LD (2014) Osteocyte-specific deletion of Fgfr1 suppresses FGF23. PLoS ONE 9:e104154PubMedPubMedCentralCrossRef

103.

Dasgupta D, Wee MJ, Reyes M, Li Y, Simm PJ, Sharma A, Schlingmann KP, Janner M, Biggin A, Lazier J, Gessner M, Chrysis D, Tuchman S, Baluarte HJ, Levine MA, Tiosano D, Insogna K, Hanley DA, Carpenter TO, Ichikawa S, Hoppe B, Konrad M, Savendahl L, Munns CF, Lee H, Juppner H, Bergwitz C (2014) Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosis. J Am Soc Nephrol 25:2366–2375PubMedPubMedCentralCrossRef

104.

Dhir G, Li D, Hakonarson H, Levine MA (2017) Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c. Bone 97:15–19PubMedCrossRef

105.

Cebeci AN, Zou M, BinEssa HA, Alzahrani AS, Al-Rijjal RA, Al-Enazi AF, Al-Mohanna FA, Cavalier E, Meyer BF, Shi Y (2019) Mutation of SGK3, a novel regulator of renal phosphate transport, causes autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab

106.

Bhandaru M, Kempe DS, Rotte A, Capuano P, Pathare G, Sopjani M, Alesutan I, Tyan L, Huang DY, Siraskar B, Judenhofer MS, Stange G, Pichler BJ, Biber J, Quintanilla-Martinez L, Wagner CA, Pearce D, Foller M, Lang F (2011) Decreased bone density and increased phosphaturia in gene-targeted mice lacking functional serum- and glucocorticoid-inducible kinase 3. Kidney Int 80:61–67PubMedPubMedCentralCrossRef

107.

Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe JY, Zelikovic I, Skorecki K (2010) A loss-of-function mutation in NaPi-IIa and renal Fanconi's syndrome. N Engl J Med 362:1102–1109PubMedCrossRef

108.

Devuyst O, Thakker RV (2010) Dent's disease. Orphanet J Rare Dis 5:28–28PubMedPubMedCentralCrossRef

109.

Glorieux FH, Scriver CR, Reade TM, Goldman H, Roseborough A (1972) Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med 287:481–487PubMedCrossRef

110.

Stickler GB, Hayles AB (1960) Rosevear JW (1965) Familial hypophosphatemic vitamin D resistant rickets: effect of increased oral calcium and phosphorus intake without high doses of vitamin D. Am J Dis Child 110:664–667CrossRef

111.

Drezner MK, Lyles KW, Haussler MR, Harrelson JM (1980) Evaluation of a role for 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of X-linked hypophosphatemic rickets and osteomalacia. J Clin Investig 66:1020–1032PubMedCrossRefPubMedCentral

112.

Costa T, Marie PJ, Scriver CR, Cole DE, Reade TM, Nogrady B, Glorieux FH, Delvin EE (1981) X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab 52:463–472PubMedCrossRef

113.

Glorieux FH, Marie PJ, Pettifor JM, Delvin EE (1980) Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 303:1023–1031PubMedCrossRef

114.

DeLacey S, Liu Z, Broyles A, El-Azab SA, Guandique CF, James BC, Imel EA (2019) Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients. Bone 127:386–392PubMedPubMedCentralCrossRef

115.

Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR (1987) Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr 111:700–704PubMedCrossRef

116.

Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325:1843–1848PubMedCrossRef

117.

Rivkeesel-Hajj-Fuleihan SAG, Brown EM, Crawford JD (1992) Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514–1518

118.

Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, Bockenhauer D, Hoff WV, Waters AM (2012) Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 27:581–588PubMedCrossRef

119.

EMA (2017) Crysvita: EPAR—Product Information. https://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004275/human_med_002224.jsp&mid=WC0b01ac058001d124

120.

FDA (2019) CRYSVITA® (burosumab-twza) injection, for subcutaneous use; Initial U.S. Approval: 2018; revised 9/2019. In: FDA (ed) https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761068Orig1s000TOC.cfm

121.

Carpenter TO, Whyte MP, Imel EA, Boot AM, Hogler W, Linglart A, Padidela R, Van't Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA (2018) Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 378:1987–1998PubMedCrossRef

122.

Carpenter TO, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Wooddell MM, Kawakami T, Ito T, Zhang X, Humphrey J, Insogna KL, Peacock M (2014) Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest 124:1587–1597PubMedPubMedCentralCrossRef

123.

Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO (2015) Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab 100:2565–2573PubMedPubMedCentralCrossRef

124.

Whyte MP, Carpenter TO, Gottesman GS, Mao M, Skrinar A, San Martin J, Imel EA (2019) Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol 7:189–199PubMedCrossRef

125.

Imel EA, Glorieux FH, Whyte MP, Munns CF, Ward LM, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Pitukcheewanont P, Sochett E, Hogler W, Muroya K, Tanaka H, Gottesman GS, Biggin A, Perwad F, Mao M, Chen CY, Skrinar A, San Martin J, Portale AA (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393:2416–2427PubMedPubMedCentralCrossRef

126.

Insogna KL, Rauch F, Kamenicky P, Ito N, Kubota T, Nakamura A, Zhang L, Mealiffe M, San Martin J, Portale AA (2019) Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm, international trial. J Bone Miner Res 34:2183–2191PubMedCrossRef

Titel: Congenital Conditions of Hypophosphatemia in Children
verfasst von: Erik Allen Imel
Publikationsdatum: 23.04.2020
Verlag: Springer US
Erschienen in: Calcified Tissue International / Ausgabe 1/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-020-00692-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Congenital Conditions of Hypophosphatemia Expressed in Adults

Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23

Role of Phosphate in Biomineralization

Phosphate as a Signaling Molecule

Phosphate Metabolism